A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · New England Journal of Medicine · 2015 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

Carola Ponzetto, Alberto Bardelli, Flavio Maina et al. · Cell · 1994 · 991 citations

Life Sciences, Cell Biology, Molecular Biology +12

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

David C. Smith, Matthew R. Smith, Christopher J. Sweeney et al. · Journal of Clinical Oncology · 2012 · 443 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

c-MET as a potential therapeutic target and biomarker in cancer

J. Rafael Sierra, Ming‐Sound Tsao · Therapeutic Advances in Medical Oncology · 2011 · 362 citations · Full text

Medicine, Oncology, Pharmacology +17